Drug class
Multikinase inhibitor; BCR::ABL1 and SRC-family tyrosine kinase inhibitor
Mechanism of action
Inhibits BCR::ABL1 and SRC-family kinases and additional kinases including c-KIT, EPHA2 and PDGFRβ. Inhibition of BCR::ABL1 kinase activity suppresses proliferation and survival of Philadelphia chromosome-positive leukaemic cells.
General use cases
- Treatment of adults with newly diagnosed chronic-phase Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML)
- Treatment of adults with chronic, accelerated or blast-phase CML resistant or intolerant to prior therapy, and selected Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) settings
- Paediatric Ph+ CML in chronic phase in eligible patients; indications and treatment lines vary by label
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
